NovaQuest Capital Management to Acquire Viamet Pharmaceuticals and the VT-1161 Antifungal Program

NovaQuest Capital to advance the clinical development of VT-1161 for the treatment of RVVC and Onychomycosis

Viamet Pharmaceuticals (NC), Inc. (“Viamet Pharmaceuticals”) today announced that it has entered into an agreement with NovaQuest Capital Management, L.L.C. (“NovaQuest Capital”) for the acquisition of Viamet Pharmaceuticals, including the company’s product candidate, VT-1161, which successfully completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis (RVVC) and onychomycosis, or fungal nail infection. Upon closing of the acquisition, Viamet Pharmaceuticals will be a portfolio company of NovaQuest Capital, which will focus on further development of VT-1161 and related assets. Viamet Pharmaceuticals is a subsidiary of Viamet Pharmaceuticals Holdings, LLC, which will retain ownership of the remaining Viamet group of companies and assets, including worldwide rights to the MIDAS (Metalloenzyme Inhibitor Design And Synthesis) technology platform and development programs addressing invasive fungal infections, oncology and orphan diseases.

Read the full press releaseCompany website